EQS-PVR: Disclosure of Shareholdings

Disclosure of Shareholdings

Submited, 18/06/2026

Notification ID: 77b1d1cb-63b3-4b8f-b0f1-bb767e0006e7

Disclosure notification concerning a single investor
Name of listed company

BB Biotech AG
 

PART 1: PERSON SUBJECT TO REPORTING OBLIGATION

Last name, first name, place of residence or company name and head office of the beneficial owner (art. 120 para. 1 FMIA) and/ or of the person who has the discretionary power to exercise the voting rights (art. 120 para. 3 FMIA):

Company: Saba Capital Management, L.P

City: New York

Country: United States of America (the)

PART 2: IN CASE OF INDIRECT PARTICIPATION

Last name, first name, place of residence or company name and head office of the person/s directly involved

PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION

Date of the act that creates the obligation to notify: 17.06.2025

Facts and circumstances triggering the obligation to notify (art. 22 para. 1 b FMIO-FINMA):

X Acquisition

Sale

Creation of a group

Change in group composition Termination of a group

Discretionary exercise of voting rights

Securities lending and comparable transactions

Exercise, non-exercise or expiration of derivative holdings

Granting (writing) of derivative holdings

Capital increase

Capital reduction

Ipso jure transfer or transfer due to a decision by a court or public authority

Change in the information subject to the obligation to notify

Other 
Total of voting rights below 3%

If the participation falls below the threshold of 3% (purchase positions and sale positions), no indication in Part 4 or Part 5 is required.

Total of voting rights <3%

PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA

Total of all purchase positions:

Total of all equity securities or equity related securities (item 1), number of voting rights that can be exercised at one’s own discretion (item 3) and derivative holdings (item 4)

Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:

 55,400,000 
 

1. Equity securities or equity related securities

1. Whether exercisable or not
2. Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

2. Securities lending and comparable transactions in equity securities

Of the equity securities mentioned in item 1 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):

3. Voting rights that can be exercised at one's own discretion

The following voting rights were delegated by a third party and can be exercised at one's own discretion.

Voting rights

Is the person who has full discretionary powers to exercise voting rights directly or indirectly controlled?

Yes  No

4. Derivative holdings

Conversion and share purchase rights (such as call-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) share sale rights and other derivative holdings:

2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

5. Securities lending and comparable transactions in derivative holdings

Of the derivative holdings mentioned in item 4 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):

PART 5: SALE POSITIONS PURSUANT TO ART. 14 PARA. 1 B FMIO-FINMA

Total of all sale positions: 
Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:

 55,400,000 

Derivative holdings

Share sale rights (such as put-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) conversion and share purchase rights and other derivative holdings:

Total

2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)